Skip to content

18F-BMS-986192 PET to Predict Durable Response to Nivolumab in NSCLC: A Novel Approach Beyond PD-L1 Immunohistochemistry.

Oct 2026 · Journal of Nuclear Medicine · 0 citations · 15 references
Medicine

Abstract

Programmed death ligand 1 (PD-L1) immunohistochemistry, the current standard biomarker for predicting response to programmed death protein 1/PD-L1 checkpoint inhibitors in non-small cell lung cancer, has moderate predictive value among others because of tumor heterogeneity and limited biopsy representation, whereas PD-L1 PET/CT using 18F-BMS-986192 enables noninvasive, whole-tumor assessment of PD-L1 expression and heterogeneity, potentially improving prediction of response to immunotherapy. Methods: In this prospective multicenter biomarker exploration study, patients with stage IV non-small cell lung cancer eligible for nivolumab-based therapies underwent baseline 18F-BMS-986192 PET/CT, 18F-FDG PET/CT, and tumor biopsy for PD-L1 immunohistochemistry before treatment initiation. The primary endpoint was durable clinical benefit, defined as progression-free survival (PFS) of 9 mo or greater, with secondary analyses assessing associations among tracer uptake, PD-L1 expression, survival outcomes, and PET-based radiomic features. Results: Of 91 enrolled patients, 77 were included in the final analysis of 18F-BMS-986192 PET/CT. Although PD-L1 immunohistochemistry did not differ between patients with PFS of less than 9 mo versus 9 mo or greater, PD-L1 PET uptake in lung lesions was significantly higher in patients with PFS of at least 9 mo (P = 0.01). Using an optimal mean SUVpeak cutoff of 2.4, PD-L1 PET demonstrated a high negative predictive value (94%) for durable clinical benefit, with significant associations for both PFS and overall survival, particularly in patients receiving first-line treatment. Tracer uptake showed no correlation with 18F-FDG uptake. Conclusion: 18F-BMS-986192 PET/CT revealed interpatient PD-L1 variability. Low uptake in lung lesions predicted poor outcomes with high negative predictive value. 18F-BMS-986192 PET/CT demonstrated stronger negative predictive value than did baseline PD-L1 immunohistochemistry in this cohort. These findings require prospective validation.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.